Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients with Relapsing Multiple Sclerosis: Results from Subgroup Analysis Based on Body Mass Index and Age from the Phase 3 ASCLEPIOS I/II Trials (P6-6.011)

This is the authors' abstract. We don't add key points for this paper.

To evaluate the prognostic value of serum neurofilament light chain (sNfL) for future disease activity according to body mass index (BMI) and age in people with relapsing multiple sclerosis (pwRMS).